Introduction
Biomedicine is in the midst a revolution signified by the near completion or completion of the decoding of the human genome and genomes of a growing number of other organisms (1) (2) (3) (4) . Two new disciplines, genomics and proteomics, are rapidly advancing in concert with this expanding knowledge and the new drive to gain a holistic view of biological systems. This systems approach is direly needed because it is abundantly clear that both the genome and proteome are dauntingly complex. The current estimate places the total number of genes in the range of 30-40,000, while the number of proteins reaches tens of millions because of processes such as protein phosphorylation, ethylation, acetylation, nitration, sulfation, glycosylation, fatty acids addition, and ubiquitination (5, 6) . Adding to this complexity is the fact that the gene products are not independent of each other but form a dynamic network involving interaction and regulation.
There are numerous examples of the application of genomic technologies, chief among those now is gene expression profiling at the messenger RNA (mRNA) level by cDNA microarray analysis that is used for cancer classification and new target identification and for studies of genetic regulatory networks (7-12). These areas have been extensively reviewed (13-18) and therefore will not be discussed in this article. In this article we will focus on the use of proteomics to increase our understandings of carcinogenesis. In cells, the mRNA molecules are translated into proteins that carry out the basic biological functions. However, there is no strict linear relationship between the mRNA and the proteins in terms of the expression level (19) . This points up the fact that proteome information lies integral to genome information in understanding the functional and physiological states of cells. Indeed, recent progress in the field of proteomics has begun to demonstrate the major impact of proteomic technologies on cancer research and treatment.
Proteomics provides the framework for the large-scale analysis of protein expression, modification, interactions, localization, and communication in cells and tissues (20) (21) (22) . To acquire information on protein expression and identity, new technologies such as protein arrays and isotope-coded affinity tag (ICAT) peptide labeling have been developed that complement with high-throughput two-dimensional gel electrophoresis (2-DE) and mass spectrometry. A number of conventional technologies such as the yeast two-hybrid system, immunohistochemistry, and transfection have also been scaled up for use in tissue microarray and cell array technologies to meet the new needs in the proteomic era. In addition, databases and mathematical modeling are becoming an increasingly important aspect of proteomics as we dig deeper and more broadly into the complex networks of the protein world.
The high-throughput analysis of proteins is not trivial and there are many caveats about reaching conclusions based on the information yielded. This is because proteins can be compartmentalized into different complexes, proteins also often undergo proteolytic cleavage or posttranslational modifications, such as phosphorylation or glycosylation, in response to environmental cues (23). Indeed, more than a hundred types of posttranslational modifications are currently known, and the complexity resulting from all of these modifications is compounded by the high level of diversity introduced by RNA alternative splicing that generates different proteins. Although encoded by the same gene, these proteins may have distinct functions. A well-cited example is the tumor suppressor p53 gene product that becomes phosphorylated at several sites after cells are insulted with DNA damaging radiation. Specifically, the phosphorylation at Ser15, Thr18, and Ser20 in the transactivation domain of p53 attenuates p53's binding to its negative regulator, mdm2, which then enhances p53's activity as a transcriptional activator (24). Another example is the two protein products encoded by alternatively spliced forms of the Fas/APO1 gene that have opposite functions-promoting and inhibiting apoptosis (25, 26) .
The major thrust of proteomics is in two directions. One is to acquire proteome data and characterize proteins in the proteome and the other is to identify protein regulatory networks. In this paper, we will review some developments in proteomic technologies, including proteome profiling and protein identification and sequencing and the current understanding of protein networks in the context of cancer research.
Protein Expression Profiling
Protein expression profiling is the global quantification of protein expression in cells, tissues, or body fluids. The objective is to identify proteins that are up-or down-regulated in a disease-specific manner.
Protein Array
Protein microarrays, or protein chips, come in several forms. In one form, crude biological samples are applied on an array of chemical surfaces capable of capturing a subset of proteins (hundreds to thousands) from the sample. The subset of proteins is then profiled by a separation strategy. Here we call this a capturing protein chip. The second form of protein chips is more specific and very analogous to cDNA microarrays. On this type of protein chip which we call, targeting protein chips, specific individual proteins such as antibodies are arrayed on a surface as probes to profile the corresponding targets and the associated complex in biological materials. In both types of chips, retained proteins on the surface are analyzed by laser desorption/ionization time-of-flight mass spectrometry (27) .
Capturing Protein Chips
The capturing protein chip is exemplified by the ProteinChip ™ System (Ciphergen, Fremont, CA, USA), which is based on SELDI (surface-enhanced laser desorption/ionization)-time of flight (TOF) mass spectrometry. SELDI-TOF technology utilizes solid supports made of aluminum or stainless steel arrayed with capturing surface that is 1 to 2 mm in diameter. The surface can have hydrophobic, hydrophilic, cationic, or anionic chromatographic supports. In this technique, small amounts of protein samples are applied directly to the surface. After the chip is washed to remove nonspecifically bound proteins, the captured peptide/protein on the surface are analyzed by TOF-MS. With this methodology, protein profiles can be obtained from even a small amount of materials and sample could be directly detected without preprocessing (28) ( Figure 1 ). This technology has been used to determine specific profiles for use in cancer classification (29, 30) . In additions, an artificial intelligence-based algorithm was used to analyze multiparametric proteomic data from the SELDI ProteinChip ™ to identify diagnostic patterns of protein expression: prostate and ovarian cancer, using serum from men and women (31, 32) . In this study, serum protein profiling was able to detect prostate cancer patients with a sensitivity and specificity of 92-100%, using age-matched healthy donors as the comparison group. In ovarian cancer (32), protein expression patterns in the serum showed 100% sensitivity and 98% specificity. This work has shown the potential of using protein profiles for the early detection of cancer, even though the identities of the proteins in the profiles are not known. In another study, fractions of serum from 20 breast cancer patients and 20 healthy women were analyzed to detect cancer markers (33). Twelve fractions collected from ion exchange chromatography were applied to the SELDI ProteinChip ™ , and 15 peaks were shown in 75% of the cancer samples but in only 25% of the normal samples. Of the 15 peaks, three were found in all cancer samples, but in none of the normal samples. The SELDI ProteinChip ™ was also used to detect protein markers in urine samples from patients with transitional cell carcinoma (TCC) (34). Multiple differences in protein were detected in samples from patients with TCC, compared with samples from patients with other urogenital diseases, and healthy donors. The TCC detection rates achieved by the individual markers ranged from 43 to 70% with specificity of 70 to 86%.
Similarly, SELDI ProteinChips ™ were used to search for markers of pancreatic cancer in pancreatic juice. Pancreatic juice was used because it has a higher concentration of pancreatic cancer proteins than other sources such as serum. One peak was detected in 67% (10/15) of cancer pancreatic juice samples and 17% (1/7) of normal samples. This peak was further identified as the hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I (35).
Targeting Protein Chip
The targeting protein chip has specific probes arrayed on solid matrices. A typical array of this type is the antibody microarray, on which antibodies to different antigens are arrayed. Antibodies can be used on this type of array because of their robust and tight interactions with their specific antigens (36). Antibodies can be arrayed on a microscope slide and probed with fluorescence-labeled proteins from test and reference samples. The antibodies on the chip then bind to the antigens in solution, resulting in quantifiable fluorescence ratios for specific proteins between two samples. Antibody arrays for high-throughput screening of antibody-antigen interactions based on ELISA (37) and coupled with enhanced chemiluminescence (ECL) (38) have also been reported. In an array format, the capturing proteins, either antibodies or antigens, are spotted onto membranes. Then protein samples are applied to the membranes. After unbound proteins are washed away, antigens or antibodies in the samples bound to their targets on the membranes are detected with horseradish peroxidase-conjugated antibody. The signals are imaged in an ECL system. With this array based system, expression of multiple cytokines and antibodies could be detected. Two examples illustrating the use of antibody arrays and cytokines arrays are given below.
The expression profile of selected proteins in LoVo colon carcinoma cells was determined using slide-based antibody microarray containing 1nl (100 µg/ml) of immobilized monoclonal antibodies (39). Cells treated with ionizing radiation showed up-regulation of apoptotic regulators, including p53, DNA fragmentation factor 40/caspase activated DNase, DNA fragmentation factor 45/inhibitor of caspase activated DNase, tumor necrosis factor-related apoptosis-inducing ligand, death receptor 5, decoy receptor 2, FLICE-like inhibitory protein, signal transducers and activators of transcription 1alpha, and uncoupling protein 2, among others. A protein antibody array was also recently used to determine the effect of connexin 43 on the expression of 43 cytokines, chemokines and growth factors in suppressing the growth of human glioblastoma (40). This study showed that monocyte chemotactic protein-1 (MCP-1) was down-regulated in connexin 43-transfected cells. The notion that MCP-1 downregulation mediates connexin 43-induced glioma suppression was supported by the observation that anti-MCP-1 antibody inhibited glioma cell growth in vitro.
Targeted protein arrays can also be used in other applications, such as, to detect interactions between different proteins, protein and DNA fragment, or protein and RNA molecules. This was illustrated in a study conducted by Ge (41) .
There are several caveats to consider when using antibody arrays. One is that the specificity of many antibodies is poor because they also react with other proteins. This may not be a problem in a size-separating system such as western blotting but constitutes a problem for array-based assays. A second concern is the stability of antibodies. Many antibodies become denatured under dry condition posing a problem in the antibody array production. Different matrices such as porous gel pad may be used to overcome this problem (42). One can envision that with future improvements in determining the antibody quality, antibody arrays will become a very useful tool for not only determining the protein expression level but also creating protein modification profiles. For example, antibodies that specifically recognize different phosphorylation sites of p53 could be arrayed on a suitable matrix, and the modifications of the p53 protein in biological samples could be profiled in an array format.
Two-dimensional Gel Electrophoresis and Mass Spectrometry
A major problem with protein arrays is the ambiguity of the protein identity, either because a mixture of proteins is detected or because there is not enough material for protein sequencing. Thus, 2-DE coupled with mass spectrometry is still commonly used to identify protein expression patterns. First introduced by Klose (43) and O'Farrell (44), 2-DE is used to separate proteins by isoelectric focusing in the first dimension and then by their apparent molecular weight in an SDS-PAGE, the second dimension. Hundreds of proteins can be well separated on a 2-DE, and many spots on the 2-DE are well characterized. Protein databases and reference maps have now been built to catalog the proteins resolved by 2-DE from various cell types in both healthy and diseased states. For example, the Expert Protein Analysis System (ExPASy) is a proteomics server and provides links to many software tools (www.expasy.org ) (45, 46) . There are also several cancerrelated databases; such as the SIENA-2DPAGE (breast carcinoma and amniotic fluid, www.bio-mol.unisi.it/2d/2d.html) (47); the Danish 2-D database (bladder cancer, http://biobase.dk/cgi-bin/celis/) (48); the PMMA-2DPAGE (colorectal carcinoma, www.pmma.pmfnk.cz/) (49); and the JPSL proteomic database (breast carcinoma cell line, www.ludwig.edu.au/jpsl/jpslhome/html) (50).
One drawback to 2-DE, however, is that the number of spots often correlates poorly with the number of different protein detected, since a single gene can give rise to multiple spots (19) due to co-and post-translational modifications and degradation intermediates (2, 3) . The other problem is the sensitivity and reproducibility of detection. This is due to the fact that proteins are expressed in cells over a wide, dynamic range of concentrations but the detection range of the staining methods is limited (19, (51) (52) (53) . Another problem with 2-DE is that the abundant proteins covering up less abundant proteins. To prevent this, pre-fractionation is often needed to effectively separate the proteins (51). Additionally, it is difficult for 2-DE to detect proteins that have very high or low isoelectric points and molecular weight, as well as membrane proteins. Adding to this is the fact that these proteins account for approximately 30% of total proteins expressed within a cell (54).
Mass spectrometry contributed significantly to the recent progress in protein identification. The classical protein identification method such as Edman degradation and amino acid composition analysis were substituted by mass spectrometry because mass spectrometry has more sensitive and highthroughput protein analysis ability. The invention of matrixassisted laser-desorption ionization (MALDI) and electrospray ionization (ESI) lead to the wide use of MS for the protein identification.
There are two approaches of protein identification by mass spectrometry. One is peptide mass fingerprinting and the other is sequence tag. Peptide mass fingerprinting is often used in conjunction with MALDI-TOF and sequence tags is usually carried out with nano-ESI tandem mass spectrometry to identify proteins (55, 56).
MALDI-TOF peptide mapping is most widely used for protein identification followed by extensive matching to search databases (MOWSE: http://srs.hgmp.mrc.ac.uk/cgibin/mowse) (57). It is also possible for ESI-MS/MS to obtain sequence tags for peptides and specially identify the proteins with help of database information (PepSea: http://195.41.108.38/pepsealntro/html. Mann, Tagldent www.expasy.ch/tools) (58-60).
The sensitivity and dynamic range of mass spectrometry for proteomic measurement have been improved. For example, its accuracy has been increased by using a more sophisticated variant of mass spectrometry called Fourier transform ion cyclotron resonance (FTICR), which is holding the ion, even collecting ions from multiple pulses, in a magnetic chamber and analyzing them in a variety of ways (61). The utilization of FTICR could be extended by combining with capillary isoelectron focusing to obtain extensive sequence information and to save experimental time comparing to alternative technologies (62).
Proteomic technologies have been used to identify cancer biomarkers (63-66). In one of these studies, Hanash et al (67) used mass spectrometry to identify a large number of proteins that are differentially expressed in the major subtypes of lung cancer. A database of proteins expressed in lung cancer (www-lecb.ncifcrf.gov/2dwgDB) (68) has now been constructed that integrates 2-DE profiles, mass spectrometry data, quantitative protein data and gene expression data at the RNA level and serves as a resource for lung cancer biomarker. The other study about protein profiling of human breast cancer cell line is screened by MALDI-TOF mass spectrometry. Obtained proteins were subjected to enzyme digestion and analyzed by MALDI-TOF MS to obtain peptide maps. The expressed proteins were identified based on molecular weight and peptide map using database-searching procedures with Protein Prospector program (http://prospector.ucsf.edu) (69,70). Another study about finding cancer biomarkers after drug treatment with 2-DE and MS was reported. In doxorubicin-treated MCF-7 human breast cell, the levels of three isoforms of heat shock protein 27 were decreased. It means that doxorubicin may partly effect on deregulation of heat shock protein 27 expression. Thus, with proteomic approach, drug treated-protein expression profile of cancer cell could be analyzed and this approach will be useful to define therapeutic target for cancer (71).
Isotope-coded Affinity Tag
2-DE and mass spectrometry remain the workhorses in the identification of proteins but they are limited to quantify proteins and peptides in complex mixtures. ICAT peptide labeling can both accurately quantify and concurrently determine the sequence identity of individual proteins in complex mixtures (72). The method is schematically illustrated in Figure 2 .
The ICAT reagents consist of three functional components: a biotin affinity tag, a polyether linker that can incorporate stable isotopes, and an iodoacetamide reactive group that specifically reacts with cysteinyl thiols. The side chains of cysteinyl residues in two reduced protein samples in different cell states are labeled with the isotopically light and heavy forms of the ICAT reagent, respectively. Then, the two samples are combined and digested with enzyme to generate peptide fragments and the cysteine-tagged peptides are isolated by avidin affinity chromatography. Thus, the isolated peptides are separated and analyzed by µLC-MS/MS. Finally, quantity and sequence of the proteins from which the tagged peptides originated are determined by automated multistage mass spectrometry (72). This method has several important advantages. The first is that membrane proteins can be identified because this experiment is carried out at the peptide level where solubility problems are insignificant. The second is that regardless of the sample amount, low-abundance proteins could be directly identified and quantified because ICAT is based on chromatographic separations. The third advantage is that selection of cysteinyl peptide reduce sample complexity because cysteinyl peptide constitute only 10% of the total peptides representing about 80% of the proteins. Therefore the analysis of proteins that are present in only small amount is possible as well as serves a powerful constraint in database searching (73). Also, Zou et al (74) devised the solid-phase isotope tagging method which is similar to ICAT. However, the coverage and sensitivity of protein identification of this method appear to be superior to ICAT.
Because the ICAT technique and solid-phase isotope tagging method depend on cysteine labeling, it will not detect proteins that do not contain a cysteine. In the yeast proteome, 8% of the proteins do not contain a cysteine. In mammalian cells, the percentage of proteins lacking a cysteine can be as high as 20% (75). To overcome the problem with the cysteine-based ICAT tags, alternative isotope coding approaches have been therefore developed (76).
A phosphoprotein isotope-coded affinity tags (PhIAT) was utilized to adapt differential isotopic labeling and biotinylation to quantitatively identify mixtures of low-abundance phosphorylation states of proteins. The PhIAT approach has same virtue of ICAT approach that a stable isotope labeling and a biotin tag make possible to proteome-wide purification and quantitation of peptides containing specific types of residues. Two equal aliquots of protein samples were labeled with 1,2-ethanedithiol containing either four alkyl hydrogen groups (EDT-D 0 ) or four alkyl deuterium (EDT-D 4 ), respectively followed by biotinylation. Then the labeled peptides were enzymatically digested and affinity isolated by immobilized avidin. Peptides were separated by capillary reversed-phase liquid chromatography and identified by tandem mass spectrometry.
Though the ICAT approach shows a big potential for determining relative protein levels, description of many functional changes of protein is limited by the fact that numerous posttranslational protein modifications may not be reflected by changes in protein levels. One of the most important posttranslational protein modifications is phosphorylation which is used to modulate protein activity and propagate signals within cellular pathways and networks (77, 78) . Thus, the identification of the phosphorylation changes in protein may lead to better understanding of protein activity.
Tissue Arrays
As we mentioned earlier, proteins are compartmentalized in cells and their expressions are often restricted in a cell specific manner in a tissue. This would mean that a whole tissue is homogenized, one can not get spatial information about the proteins, which can be very important. For example, if a protein is overexpressed in a tumor tissue and thus may serve as target for treatment, it would be very important to know whether this protein is overexpressed in tumor cells or in other cells such as the endothelium cells of the blood vessel in the tumor. Further, it would be important to know whether the protein is a nuclear protein or a membrane protein. For a membrane protein that is specifically expressed in the endothelium cells in the tumor, strategies such as an in vivo phage peptide display binding assay would then be used to identify binding peptides that could serve as a vehicle for drug delivery in cancer treatment. Some studies in this area have already been carried out (79, 80) .
A scaled-up version of immunohistochemical analysis, tissue microarray (TMAs) technique that can localize protein expression has now been developed. TMAs allow the immunohistochemical analysis of 500 to 1000 samples simultaneously (81). Tissue microarrays are composite paraffin blocks constructed by extracting cylindrical tissue core "biopsies" from different paraffin donor blocks and reembedding them into a single recipient (microarray) block at defined array coordinates. This technique rapidly visualizes molecular targets at the DNA, RNA or protein level in thousands of tissue specimens at a time. By revealing the cellular localization, prevalence, and clinical significance of candidate genes, tissue microarrays are ideally suited to genomics-based diagnostic and drug target discovery. However, TMAs technology has both advantages and disadvantages. Advantages are that it rapidly assesses and validates new molecular markers in a large number of tumors, with the maximal conservation and utilization of irreplaceable human archival tissue. Illustrating the rapidity of the technique is the experience of Schraml and colleagues (82) who were able to conduct three FISH experiments analyzing the amplification of three different oncogenes (CCND1, CMYC, and ERBB2) in 397 tumors in less than a week. A disadvantage of TMA is that a single core (typically 0.6-2.0 mm in diameter) is not representative of the heterogeneous parent tissues from which it comes, and therefore the prevalence of a given molecular alteration may be underestimated. The solution to this is to use larger biopsy cores (1.0-2.0 mm in diameter) and multiple cores from different regions of the donor block or cores from several different donor blocks from the same patient. The use of larger samples does not, however, ensure the accurate assessment of heterogeneity because the sample size is still small (83). Ultimately, the number of tissue cores from different regions depends on the experiment (84).
Tissue microarray also makes possible the high-throughput analysis of genetic alterations that contribute to cancer development and progression (85). For example, in the study of tumor progression, high-density tissue microarrays were used to detect gene expression changes of 418 brain tumors. Strong expression of IGFBP2 was associated with progression and poor patient survival in diffuse astrocytomas (86).
Tissue microarray technology has also been used to analyze frequencies of molecular alterations in large numbers of tumor specimens (87, 88) . Immunohistochemical staining for tumor-associated proteins is widely used to identify novel prognostic markers and it has been used in some studies of breast cancer (89, 90) .
Cell Arrays
For elucidating the functions of the large set of genes in mammalian cells, high-throughput cell microarrays have also been developed (91). In these methods, plasmid DNAs in an aqueous gelatin solution are printed at high density on a glass slide along with a lipid transfection reagent. The slide is then placed in a cell culture dish and covered with a lawn of mammalian cells in medium. Cells growing on the DNA spots are transfected, which drives the expression of specific proteins in spatially distinct groups of cells. The cell microarrays could be substituted for protein microarray, because protein microarray needs a large numbers of purified protein that is hard to keep the stable condition.
Laser Capture Microdissection
When working with clinical tissues, heterogeneity always comes into play. Tumor cells are often contaminated with normal stromal cells, infiltrating lymphocytes, fibroblasts, and blood vessel cells. If one desires to gain insight into molecular events only in tumor cells, those cells should be isolated. Laser capture microdissection (LCM) was developed for this purpose (92). LCM uses a laser beam and a thermoplastic polymer transfer film on the back of a transfer cap. The cap is placed on the tissue and a laser pulse focally activates the transfer film to extract the selected cells which are adherent to the transfer cap (92). Proteins, DNAs, and RNAs purified from LCM isolated cells have been successfully used in combination with 2DE, SELDI, real-time PCR, and microarray experiments (93-95).
Protein Interaction Networks
Application of the high-throughput technologies described above has already generated a large amount of data on proteins, heralding the era of protein information explosion. With this has come new challenges and new opportunities. The challenges include how to approach information processing, interpretation, and presentation. At the same time, the technology offers researchers an unprecedented opportunity to understand protein regulatory networks both in the physical and logical nature.
As we already know from the abundance of information on cellular pathways, proteins form highly regulated complexes that perform important cellular functions, such as cell cycle and apoptosis control (96, 97) . It is estimated that every protein has at least five interacting partners (98). This implies that proteins form a complicated network in the cell with farreaching effects, such that a change in one node of the net-work can lead to changes in proteins that may not physically associate with the initiating protein. In other words, on top of the physical protein interactions, which constitute local pathways, there is logical relationship among the cellular proteins. Understanding this logical relationship in the protein network will help us understand what happens when the node in the network is perturbed. This has an immense bearing on understanding of the effect of a local mutational change on the whole cell system and determining the best place to intervene therapeutically. Without large-scale proteomic data, such a network cannot be constructed.
There are currently three approaches for exploring genomewide protein interactions. One is laboratory-based, largescale screening for protein interactions, which is exemplified by the yeast two-hybrid system. A system developed by Ito et al (99, 100) can effectively examine two-hybrid interactions in all possible combinations between approximately 6,000 proteins of the yeast Saccharomyces cerevisiae.
Although this technology has some limits when applied to the human system because of the complicated posttranslational modifications that occur in the human cell, it can serve as a prototype for research in the human cell.
The second approach is a combined experimental and computational tool. Starting with the information of protein-protein interaction domains revealed by genome sequences, Tong et al. (101) develop a strategy to computationally predict SH3 domain protein-protein interaction networks by means of phage display-selected peptides with large-scale two-hybrid physical interaction tests. This approach would be useful to construct a particularly interesting network.
The third one is computationally based information processing using published data of protein interactions. The published interaction data from thousands of small-scale experiments over the years can also be collected and used to generate interaction networks . Recently, several such databases of interacting proteins have been compiled that can serve as valuable resources for network construction (102). These databases include DIP, which contains data on experimentally determined protein-protein interactions (103, 104); BIND, which includes data on a variety of interactions including protein-protein, protein-RNA, protein-DNA, and proteinsmall molecule interactions (105, 106); MIPS, which provides protein sequence information for yeast and other model organisms, as well as interaction data for yeast (107); PROTEOME, which contains information on many biological aspects of proteins (108); PRONET, a private database of protein interactions funded by Doubletwist and Myriad; CURAGEN, which consists of data on yeast protein interactions documented by the laboratory of S field and Curagen (109); and PIM, which includes data on the interactions of the pathogenic bacterium Helicobacter pylori (110). Schwikowski et al. (111) and Tucker et al. (98) used these databases to generate yeast protein networks and functional group interaction maps. Interestingly, Tucker et al. (98) have noticed that the most of core proteins connecting different functional pathways are associated with disease, given central roles in growth control and gene regulation. This phenomenon is not surprising since the disease proteins are typically the most interesting and studied and thus have the most complete sets of interaction data. Therefore, we can use these data to construct disease-related interaction networks. An example is the interaction map of cancer-related proteins generated by the Myriad Pronet software (www.myriad-pronet.com) based on the signaling pathway of the tumor-suppressor BRCA1 (98).
Concluding Remarks
The recent progress in biology has made us even more aware of the complexity of biological systems. Apart from the genome sequencing effort showing us that the components (e.g., genes and proteins) are numerous in the systems, we become increasingly clear that these parts of the biological systems are not linear and static in their relationship to each other. Instead, biological systems are highly nonlinear and dynamic. By the same token, however, the tumorigenesis process is nonlinear and dynamic, which makes it more difficult to develop effective interventions. The challenge right now is to obtain comprehensive information on the parts of the system in a parallel fashion and then to assemble the parts into a systems view.
We have reviewed here the recent developments in highthroughput proteomics technology that will give cancer researchers more powerful tools with which to study cancer. In the coming years, the increasing amount of data will be used to build mathematical models, which will provide new insights into the disease mechanisms, and this information in turn will be applied to the development of more effective therapeutic interventions. 
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